$7.9B Non-Small Cell Lung Cancer Market: Just The Tip Of The Iceberg For Benitec's Tribetarna
- NSCLC market is forecast to be worth $7.9B by 2020.
- Benitec's Tribetarna pre-clinical studies shows substantial increases in survival rates.
- Tribetarna is an enhancement to standard chemotherapy, not a replacement for it.
- Tribetarna silences the TUBB3 gene which has been associated with chemotherapy resistance in NSCLC and many other cancers.
- The market for a TUBB3 gene silencing/chemo cancer therapy will be over $20B in 5-6 years time.
- The cost of health care has been forecast to escalate significantly.
- A change in the health care paradigm is required if health payers are to keep pace with the costs of disease standards of care.
- Benitec Biopharma is one company with the paradigm-changing technology that could be the answer to health payers' prayers.
- Early adopters of the new health care model, such as Benitec Biopharma, are set to corner the market for several major disease types.
- There is an opportunity for retail and corporate investors as big pharma may get the message and start investing in the new paradigm.
Benitec: An Undiscovered Biotechnology With A Twist
There are no Transcripts on BNIKF.
We currently have no Breaking News on this stock.
BNIKF vs. ETF Alternatives
Other News & PR